Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management

Community Oncology

Volumn 9, Issue 2, 2012, Pages 46-55

  Wood, Laura S ^a   Gornell, Suzanne ^b   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTOCHROME P450 INHIBITOR; EVEROLIMUS; KETOCONAZOLE; PAZOPANIB; PLACEBO; PROBIOTIC AGENT; RIFAMPICIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EPISTAXIS; ERYTHROCYTOSIS; FATIGUE; HAND FOOT SYNDROME; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NURSE ATTITUDE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT EDUCATION; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION;

EID: 84857465780     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmonc.2011.11.002     Document Type: Review

References (51)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4): 843-852.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.2.2011. National Comprehensive Cancer Center. http://www.nccn.org/index.asp. Accessed February 25, 2011.
4. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028-1043.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus in-terferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-124.
8. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, inter-feron alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
9. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everoli-mus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
10. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.
11. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144-2150.
12. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605): 2103-2111.
13. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bev-acizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
14. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus inter-feron alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26(33):5422-5428.
15. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
16. Sternberg CN, Hawkins RE, Szczylik C, et al. Randomized, double-blind phase III study of pazopanib in patients with advanced/ metastatic renal cell carcinoma (MRCC): final overall survival (OS) results. Ann Oncol. 2010;21(suppl 8):viii10.
17. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical anti-angiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272-7283.
18. Kelly RJ, Rixe O. Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol. 2009;4(4): 297-305.
19. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005;23(24):5464-5473.
20. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24): 5474-5483.
21. Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol. 2010;65(3):563-570.
22. Tortorici M, Chen Y, Hee B, Ni G, Pithavala Y. Effect of food on the pharmacokinetics (PK) of axitinib in healthy volunteers (HVs). EJC Supplements. 2010;8:71.
23. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975-984.
24. Motzer RJ, de La Motte Rouge T, Harzstark AL, et al. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trial [ASCO abstract 4547]. J Clin Oncol. 2011;29(suppl):S300.
25. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(27):4462-4468.
26. Rini BI, Escudier B, Tomczak P, et al. Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase 3 AXIS trial [ASCO abstract 4503]. J Clin Oncol. 2011; 29(suppl):S289.
27. Pithavala YK, Tong W, Mount J, et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs. 2010 doi:10.1007/s10637-10010-19511-10636.
28. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30(6):591-601.
29. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs. 2009;20(1):81-82.
30. Fishman MN, Carducci M, Bair AH, Chen Y, Rini BI. Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma (RCC) patients. Ann Oncol. 2010;21(suppl 8):284.
31. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652-658.
32. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol. 2007;18(6):1117.
33. Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) [ASCO abstract 5045]. J Clin Oncol. 2009;27(suppl):S245.
34. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807-815.
35. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010; 102(1):14-25.
36. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596-604.
37. Wood LS. Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs. 2009;13(suppl): 13-18.
38. Wood LS. New therapeutic strategies for renal cell carcinoma. Urol Nurs. 2010;30(1):40-53.
39. Edmonds K, Spencer-Shaw A. Managing adverse events associated with sorafenib in renal cell carcinoma. Br J Nurs. 2010;19:58-60.
40. Creel PA. Management of mTOR inhibitor side effects. Clin J Oncol Nurs. 2009;13(suppl):19-23.
41. Esper P, Gale D, Muehlbauer P. What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs. 2007;11(15):659-666.
42. Moldawer NP, Figlin R. Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. Oncol Nurs Forum. 2008;35(4):699-708.
43. Wood LS. Practical considerations in the management of hand- foot skin reaction caused by multikinase inhibitors. Community Oncol. 2010;7:23-29.
44. Larkin JM, Pyle LM, Gore ME. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist. 2010;15: 1135-1146.
45. Vakkalanka BK, Elson P, Wood L, et al. Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC) [ASCO abstract 16045]. J Clin Oncol. 2008;26(suppl).
46. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2011. doi:10.1007/s10637-10011-19637-10631.
47. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-83.
48. Kollmannsberger C, Bjarnason G, Burnett P, et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist. 2011;16:543-553.
49. Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) [ASCO abstract 5126]. J Clin Oncol. 2008;26(suppl):S280.
50. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117: 534-544.
51. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378:1931-1939.